These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 26539835)

  • 21. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
    Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes.
    Höbaus C; Ursli M; Yussef SM; Wrba T; Koppensteiner R; Schernthaner GH
    Vasc Med; 2021 Feb; 26(1):11-17. PubMed ID: 33448911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble urokinase plasminogen activator receptor and decline in kidney function among patients without kidney disease.
    Iversen E; Kallemose T; Hornum M; Bengaard AK; Nehlin JO; Rasmussen LJH; Sandholdt H; Tavenier J; Feldt-Rasmussen B; Andersen O; Eugen-Olsen J; Houlind MB
    Clin Kidney J; 2022 Aug; 15(8):1534-1541. PubMed ID: 35892012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble urokinase-type plasminogen activator receptor (suPAR) is a risk indicator for eGFR loss in kidney transplant recipients.
    Jehn U; Schütte-Nütgen K; Henke U; Pavenstädt H; Suwelack B; Reuter S
    Sci Rep; 2021 Feb; 11(1):3713. PubMed ID: 33580120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma Soluble Urokinase Receptor Level Is Correlated with Podocytes Damage in Patients with IgA Nephropathy.
    Zhao Y; Liu L; Huang J; Shi S; Lv J; Liu G; Zhao M; Zhang H
    PLoS One; 2015; 10(7):e0132869. PubMed ID: 26167688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
    Persson M; Engström G; Björkbacka H; Hedblad B
    Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis.
    Huang F; Li Y; Xu R; Cheng A; Lv Y; Liu Q
    Mediators Inflamm; 2020; 2020():7850179. PubMed ID: 32322165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.
    Alachkar N; Li J; Matar D; Vujjini V; Alasfar S; Tracy M; Reiser J; Wei C
    BMC Nephrol; 2018 Dec; 19(1):361. PubMed ID: 30558559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Associations of Plasma Biomarkers of Inflammation, Fibrosis, and Kidney Tubular Injury With Progression of Diabetic Kidney Disease: A Cohort Study.
    Gutiérrez OM; Shlipak MG; Katz R; Waikar SS; Greenberg JH; Schrauben SJ; Coca S; Parikh CR; Vasan RS; Feldman HI; Kimmel PL; Cushman M; Bonventre JV; Sarnak MJ; Ix JH
    Am J Kidney Dis; 2022 Jun; 79(6):849-857.e1. PubMed ID: 34752914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urinary Potassium Excretion and Renal and Cardiovascular Complications in Patients with Type 2 Diabetes and Normal Renal Function.
    Araki S; Haneda M; Koya D; Kondo K; Tanaka S; Arima H; Kume S; Nakazawa J; Chin-Kanasaki M; Ugi S; Kawai H; Araki H; Uzu T; Maegawa H
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2152-8. PubMed ID: 26563378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. suPAR and chronic kidney disease-a podocyte story.
    Zeier M; Reiser J
    Pflugers Arch; 2017 Aug; 469(7-8):1017-1020. PubMed ID: 28689240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
    Chonchol M; Gitomer B; Isakova T; Cai X; Salusky I; Pereira R; Abebe K; Torres V; Steinman TI; Grantham JJ; Chapman AB; Schrier RW; Wolf M
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1461-1469. PubMed ID: 28705885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.
    Drechsler C; Hayek SS; Wei C; Sever S; Genser B; Krane V; Meinitzer A; März W; Wanner C; Reiser J
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1265-1273. PubMed ID: 28495863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.
    Winnicki W; Sunder-Plassmann G; Sengölge G; Handisurya A; Herkner H; Kornauth C; Bielesz B; Wagner L; Kikić Ž; Pajenda S; Reiter T; Schairer B; Schmidt A
    Sci Rep; 2019 Sep; 9(1):13783. PubMed ID: 31551522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease.
    Mehta A; Desai SR; Ko YA; Liu C; Dhindsa DS; Nayak A; Hooda A; Martini MA; Ejaz K; Sperling LS; Reiser J; Hayek SS; Quyyumi AA
    J Am Heart Assoc; 2020 Mar; 9(5):e015457. PubMed ID: 32089048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.
    Jin J; Li YW; He Q
    Transplant Proc; 2015; 47(6):1760-5. PubMed ID: 26293047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble Urokinase Receptor and Acute Kidney Injury.
    Hayek SS; Leaf DE; Samman Tahhan A; Raad M; Sharma S; Waikar SS; Sever S; Camacho A; Wang X; Dande RR; Ibrahim NE; Baron RM; Altintas MM; Wei C; Sheikh-Hamad D; Pan JS; Holliday MW; Januzzi JL; Weisbord SD; Quyyumi AA; Reiser J
    N Engl J Med; 2020 Jan; 382(5):416-426. PubMed ID: 31995687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated serum homocysteine is a predictor of accelerated decline in renal function and chronic kidney disease: A historical prospective study.
    Levi A; Cohen E; Levi M; Goldberg E; Garty M; Krause I
    Eur J Intern Med; 2014 Dec; 25(10):951-5. PubMed ID: 25457436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis].
    Segarra A; Jatem E; Quiles MT; Arbós MA; Ostos H; Valtierra N; Carnicer C; Salcedo MT
    Nefrologia; 2014; 34(1):53-61. PubMed ID: 24463863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease.
    Meijers B; Poesen R; Claes K; Dietrich R; Bammens B; Sprangers B; Naesens M; Storr M; Kuypers D; Evenepoel P
    Kidney Int; 2015 Jan; 87(1):210-6. PubMed ID: 24897037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.